A single clinical trial endpoint change, tucked into a regulatory filing plan, could reshape how a common cause of blindness is treated. That is the core bet Ocular Therapeutix is making as it briefs investors today on its path to market for AXPAXLI, a drug candidate for wet age-related macular degeneration. The company has secured FDA alignment on a submission strategy that hinges on combining efficacy and safety data from its completed SOL-1 trial with interim safety data from the ongoing SOL-R study.
The full New Drug Application is targeted for the fourth quarter of 2026. But the real weight of today’s event rests on a single, later-stage question: can AXPAXLI prove it is better than the current standard of care, aflibercept, at 96 weeks?
That question was added as a new secondary endpoint in SOL-R. The trial will stay masked through that 96-week mark, with results expected in the first quarter of 2028. If the data show superiority, the potential label for AXPAXLI would carry differentiation that supports broad global adoption.
If not, the drug still has a path—but the ceiling on its commercial value drops. The stakes here are concrete.
Wet AMD is a leading cause of vision loss in older adults. Current treatments require frequent injections into the eye, often every four to eight weeks. AXPAXLI is designed as a longer-lasting therapy.
The SOL-R endpoint change is a deliberate escalation: the company is not just seeking approval, it is seeking a competitive claim of superiority against a widely used drug. Ocular Therapeutix is also filing under the 505(b)(2) regulatory pathway. That mechanism allows the FDA to rely on safety and efficacy data from previously approved drugs, potentially shaving up to 60 days off the review timeline.
The move signals urgency. The company wants this drug reviewed fast, but not at the expense of rigor.
The FDA has signed off on the plan. Beyond the wet AMD program, the company is streamlining its diabetic retinopathy work. Following strong results from SOL-1, the HELIOS-3 trial has been prioritized as a potential single registrational study.
That trial will evaluate AXPAXLI dosed once every 12 months. If successful, it would represent a step-change in treatment frequency for a disease that also requires repeated injections.
What is genuinely at risk is not just a single product launch. It is the question of whether a sustained-release therapy can displace a generation of injectable biologics that have dominated retinal care for over a decade. Aflibercept, made by Regeneron, generated billions in annual sales.
Ocular Therapeutix is a smaller company trying to break into that market with a novel delivery mechanism. The 2026 NDA submission date is two years away. The 2028 superiority data is four years out.
Between now and then, the company must execute on enrollment, data collection, and manufacturing scale-up. The FDA alignment announced today removes one major source of regulatory uncertainty.
It does not remove the clinical or commercial risk. For investors, the message is clear: the company has a defined, FDA-agreed path to filing. The next mileposts are execution milestones, not regulatory guesswork.
Whether that is enough to justify the valuation will depend on what the SOL-R data show in 2028.
